Origins of FL genes

Tier 1 FL genes

49 total

Gene Summary First FL study Other entities QC result
ARID1A Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FE1, aSHM Krysiak et al 2,3,rossiCodingGenomeSplenic2012c?,wienandGenomicAnalysesFlowsorted2019b?
ATP6AP1 Tier 1 GEokosunRecurrentMTORC1activatingRRAGC2016a? Okosun et al
ATP6V1B2 Tier 1 GEokosunRecurrentMTORC1activatingRRAGC2016a? Okosun et al
B2M Tier 1 GE4, FEchalla-malladiCombinedGeneticInactivationa?, aSHM Morin et al 5,reichelFlowSortingExome2015a?
BCL2 Tier 1 GE4, FE6, aSHM Morin et al 7,burkhardtClinicalRelevanceMolecular2022b?,sarkozyMutationalLandscapeGray2021a?
BCL7A Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FEbalinas-gaviraFrequentMutationsAminoterminal2020b?, aSHM Krysiak et al 4,8,reichelFlowSortingExome2015a?
BTK Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al albuquerqueEnhancingKnowledgeDiscovery2017a?
CARD11 Tier 1 GE4, FE9, CEzhaoExpressionPrognosticValue2016?, aSHM Morin et al 9,10,yanBCRTLRSignaling2012a?
CCND3 Tier 1 GE4, FE11, aSHM Morin et al 12,13,richterRecurrentMutationID32012a?
CD83 Tier 1 GErussler-germainMutationsAssociatedProgression2023b?, aSHM Russler et al 14,15,dunsCharacterizationDLBCLPMBL2021b?
CREBBP Tier 1 GEpasqualucciInactivatingMutationsAcetyltransferase2011a?, FEpasqualucciInactivatingMutationsAcetyltransferase2011a?, aSHM Pasqualucci et al 2,16,dunsCharacterizationDLBCLPMBL2021b?
CTSS Tier 1 GEbarariaCathepsinAlterationsInduce2020c? Bararia et al
EEF1A1 Tier 1 GEhubschmannMutationalMechanismsShaping2021b?, CEgongExpressionClinicalValue2021?, aSHM Hubschmann et al reichelFlowSortingExome2015a?
EP300 Tier 1 GEpasqualucciInactivatingMutationsAcetyltransferase2011a?, FEpasqualucciInactivatingMutationsAcetyltransferase2011a?, aSHM Pasqualucci et al rossiCodingGenomeSplenic2012c?
EZH2 Tier 1 GEmorinSomaticMutationsAltering2010a?, FEyapSomaticMutationsEZH22011b?, aSHM Morin et al 2,mottokIntegrativeGenomicAnalysis2019b?
FOXO1 Tier 1 GE4, FE17, CE17, aSHM Morin et al 11,dunsCharacterizationDLBCLPMBL2021b?
GNA13 Tier 1 GE4, FEmuppidiLossSignalingGa132014b?, aSHM Morin et al 2,reichelFlowSortingExome2015a?
HIST1H1B Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al chapuyMolecularSubtypesDiffuse2018b?,sarkozyMutationalLandscapeGray2021a?
HIST1H1C Tier 1 GE4, aSHM Morin et al 15
HIST1H1D Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al 13,14
HIST1H1E Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al 8,lohrDiscoveryPrioritizationSomatic2012a?,reichelFlowSortingExome2015a?
HIST1H2AC Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al 14
HIST1H2AG Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al 14,15,rossiCodingGenomeSplenic2012c?
HIST1H2AM Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al 15,chapuyMolecularSubtypesDiffuse2018b?
HIST1H2BC Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al lohrDiscoveryPrioritizationSomatic2012a?,mottokIntegrativeGenomicAnalysis2019b?
HIST1H2BD Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HIST1H2BG Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HIST1H3G Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HIST1H3I Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 15
HVCN1 Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al chapuyMolecularSubtypesDiffuse2018b?
IRF4 Tier 1 GE18, aSHM Dreval et al 4,mottokIntegrativeGenomicAnalysis2019b?
IRF8 Tier 1 GE4, FE19, aSHM Morin et al 15,mottokIntegrativeGenomicAnalysis2019b?
KLHL6 Tier 1 GE4, FE20, aSHM Morin et al 21
KMT2D Tier 1 GE4, FE22, CE23, aSHM Morin et al 8,12,24,rossiCodingGenomeSplenic2012c?
MAP2K1 Tier 1 GElouissaintPediatrictypeNodalFollicular2016a?, aSHM Louissaint et al 25
MEF2B Tier 1 GE4, FE26, aSHM Morin et al 24
PIM1 Tier 1 GE18, CE27, aSHM Dreval et al burkhardtClinicalRelevanceMolecular2022b?,dunsCharacterizationDLBCLPMBL2021b?,pasqualucciHypermutationMultipleProtooncogenes2001a?
POU2AF1 Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al chapuyMolecularSubtypesDiffuse2018b?
POU2F2 Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FEhodsonRegulationNormalBcell2016a?, aSHM Krysiak et al lohrDiscoveryPrioritizationSomatic2012a?
RRAGC Tier 1 GEokosunRecurrentMTORC1activatingRRAGC2016a?, FEortega-molinaOncogenicRagGTPase2019b?, aSHM Okosun et al
SGK1 Tier 1 GE4, FEhartmannHighlyRecurrentMutations2016b?, CE27, aSHM Morin et al dunsCharacterizationDLBCLPMBL2021b?
SMARCA4 Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FE28, aSHM Krysiak et al 29,nadeuGenomicEpigenomicInsights2020b?,richterRecurrentMutationID32012a?
STAT6 Tier 1 GEyildizActivatingSTAT6Mutations2015c?, FEyildizActivatingSTAT6Mutations2015c?, aSHM Yildiz et al ritzRecurrentMutationsSTAT62009a?
TBL1XR1 Tier 1 GE, FEventuruttiTBL1XR1MutationsDrive2020b?, aSHM lohrDiscoveryPrioritizationSomatic2012a?,rossiCodingGenomeSplenic2012c?
TMSB4X Tier 1 GE, aSHM 3
TNFAIP3 Tier 1 GE, FEcompagnoMutationsMultipleGenes2009a?, aSHM compagnoMutationsMultipleGenes2009a?,rossiAlterationBIRC3Multiple2011a?,schmitzTNFAIP3A20Tumor2009a?
TNFRSF14 Tier 1 GEcheungAcquiredTNFRSF14Mutations2010a?, CE27, aSHM Cheung et al 4,spinaGeneticsNodalMarginal2016b?
TP53 Tier 1 GE4, FErowhTp53DeletionLineage2011?, aSHM Morin et al 24,30,lohrDiscoveryPrioritizationSomatic2012a?,rossiCodingGenomeSplenic2012c?,tiacciPervasiveMutationsJAKSTAT2018b?
VMA21 Tier 1 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al

Tier 2 FL genes

64 total

Gene Summary First FL study Other entities QC result
ABL2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
ACTB Tier 2 GE18, aSHM Dreval et al lohrDiscoveryPrioritizationSomatic2012a?,wienandGenomicAnalysesFlowsorted2019b?
ACTG1 Tier 2 GEhubschmannMutationalMechanismsShaping2021b?, aSHM Hubschmann et al 12,spinaGeneticsNodalMarginal2016b?
ATP6V1A Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
BCL10 Tier 2 GErussler-germainMutationsAssociatedProgression2023b?, FE31, aSHM Russler et al 4,spinaGeneticsNodalMarginal2016b?
BCL6 Tier 2 GE18, FE6, aSHM Dreval et al 2,4
BIRC6 Tier 2 GE, aSHM 29,sarkozyMutationalLandscapeGray2021a?
BTG1 Tier 2 GE18, FEmlynarczykBTG1MutationYields2023b?, aSHM Dreval et al 4,burkhardtClinicalRelevanceMolecular2022b?,sarkozyMutationalLandscapeGray2021a?
BTG2 Tier 2 GE18, CE32, aSHM Dreval et al 2,4
CD70 Tier 2 GErussler-germainMutationsAssociatedProgression2023b?, aSHM Russler et al 4
CD79B Tier 2 GE18, FE33, aSHM Dreval et al 4,15
CDC42BPB Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al spinaGeneticsNodalMarginal2016b?
CILP Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
CPNE8 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
CXCR4 Tier 2 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al 15,34
CYP2A6 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
DDX3X Tier 2 GE, FE35, CEkizhakeyilDDX3XLossAdverse2021?, aSHM 11,29,mottokIntegrativeGenomicAnalysis2019b?
DHX15 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
DTX1 Tier 2 GE, FE36, CEmerirantaDeltex1MutationsPredict2017b?, aSHM 2,3,37,rossiCodingGenomeSplenic2012c?
DUSP2 Tier 2 GE18, aSHM Dreval et al dunsCharacterizationDLBCLPMBL2021b?,lohrDiscoveryPrioritizationSomatic2012a?
EBF1 Tier 2 GE, aSHM 38,39,reichelFlowSortingExome2015a?
EGR1 Tier 2 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al reichelFlowSortingExome2015a?,rossiCodingGenomeSplenic2012c?
FAS Tier 2 GE, FE40, aSHM 41,spinaGeneticsNodalMarginal2016b?
FZR1 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
GBP7 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
GNAI2 Tier 2 GE, aSHM 8,14
GRM6 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
HIST1H2BM Tier 2 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HIST1H3B Tier 2 GE, aSHM lohrDiscoveryPrioritizationSomatic2012a?,reichelFlowSortingExome2015a?
HLA-B Tier 2 GE, aSHM lohrDiscoveryPrioritizationSomatic2012a?,wienandGenomicAnalysesFlowsorted2019b?
IGLL5 Tier 2 GErussler-germainMutationsAssociatedProgression2023b?, aSHM Russler et al 12,15,chapuyMolecularSubtypesDiffuse2018b?
ITPKB Tier 2 GE18, aSHM Dreval et al reichelFlowSortingExome2015a?,schmitzGeneticsPathogenesisDiffuse2018a?
JUP Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
KIR3DL1 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
KLF2 Tier 2 GE18, aSHM Dreval et al 12,13,42
LAPTM5 Tier 2 GEhubschmannMutationalMechanismsShaping2021b?, aSHM Hubschmann et al
LTB Tier 2 GE18, aSHM Dreval et al 12,chapuyMolecularSubtypesDiffuse2018b?
MAGEC1 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
MAP7D1 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
MEF2C Tier 2 GE, FE43, aSHM 44
MGEA5 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
MKI67 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al 11
MYC Tier 2 GE, FE45, CE46, aSHM 13,47,dunsCharacterizationDLBCLPMBL2021b?,pasqualucciHypermutationMultipleProtooncogenes2001a?
MYCBP2 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
MYD88 Tier 2 GE18, FEngoOncogenicallyActiveMYD882011a?, CE27, aSHM Dreval et al ngoOncogenicallyActiveMYD882011a?,yanBCRTLRSignaling2012a?
NFKBIA Tier 2 GErussler-germainMutationsAssociatedProgression2023b?, aSHM Russler et al 48,wienandGenomicAnalysesFlowsorted2019b?
OR8H2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
P2RY8 Tier 2 GE18, FEmuppidiLossSignalingGa132014b?, aSHM Dreval et al lohrDiscoveryPrioritizationSomatic2012a?,muppidiLossSignalingGa132014b?
PDS5B Tier 2 GEhubschmannMutationalMechanismsShaping2021b?, aSHM Hubschmann et al 14
PPP4C Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
PRKDC Tier 2 GEhubschmannMutationalMechanismsShaping2021b?, aSHM Hubschmann et al schmitzGeneticsPathogenesisDiffuse2018a?
PTPRD Tier 2 GE18, aSHM Dreval et al spinaGeneticsNodalMarginal2016b?
PZP Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
RBM6 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
S1PR2 Tier 2 GE18, FE49, aSHM Dreval et al 4,muppidiLossSignalingGa132014b?
SHROOM3 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
SOCS1 Tier 2 GE18, FEmelznerBiallelicMutationSOCS12005a?, aSHM Dreval et al 4,wenigerMutationsTumorSuppressor2006a?
SRRM2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b?, aSHM Russler et al 14
STAB2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
TMEM30A Tier 2 GE4, FEennishiTMEM30ALossoffunctionMutations2020b?, CEennishiTMEM30ALossoffunctionMutations2020b?, aSHM Morin et al
TPP1 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
XIRP2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
ZC3H12A Tier 2 GE, aSHM chapuyMolecularSubtypesDiffuse2018b?
ZNF608 Tier 2 GEkrysiakRecurrentSomaticMutations2017b?, aSHM Krysiak et al 14

Tier 3 FL genes

0 total

Gene Summary First FL study Other entities QC result

References

1.
Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell. 2024 Apr 8;42(4):583–604.e11.
2.
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012 Dec;44(12):1321–1325. PMCID: PMC3674561
3.
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:1398–1403. PMCID: PMC3557051
4.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298–303. PMCID: PMC3210554
5.
Pararajalingam P, Coyle KM, Arthur SE, Thomas N, Alcaide M, Meissner B, Boyle M, Qureshi Q, Grande BM, Rushton C, Slack GW, Mungall AJ, Tam CS, Agarwal R, Dawson SJ, Lenz G, Balasubramanian S, Gascoyne RD, Steidl C, Connors J, Villa D, Audas TE, Marra MA, Johnson NA, Scott DW, Morin RD. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020 Jul 30;136(5):572–584. PMCID: PMC7440974
6.
Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, Dreval K, Wong JCH, Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin RD, Khiabanian H, Pasqualucci L, Dalla-Favera R. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature. 2022 Jul;607(7920):808–815. PMCID: PMC9583699
7.
Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin’s lymphomas. Blood. 1992 Jan 1;79(1):229–237.
8.
Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313–1324. PMCID: PMC6428665
9.
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008 Mar;319(5870):1676–1679.
10.
Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W, Galazka K, Dlugosz-Danecka M, Machaczka M, Zhang H, Peng R, Morin RD, Rosenquist R, Sander B, Pan-Hammarström Q. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget. 2016 Jun 21;7(25):38180–38190. PMCID: PMC5122381
11.
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867
12.
Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF, Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW, Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A, Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2020 Jan;34(1):151–166.
13.
Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles G, Traverse-Glehen A. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
14.
Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992
15.
Panea R, Love C, Shingleton JR, Reddy A, Bailey J, Moormann A, Otieno J, Ong’echa J, Oduor C, Schroêder K, Masalu N, Chao N, Agajanian M, Major M, Fedoriw Y, Richards K, Rymkiewicz G, Miles R, Alobeid B, Bhagat G, Flowers C, Ondrejka S, Hsi E, Choi W, Au-Yeung R, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig M, Waldrop A, Dave T, Thakkar D, Sahay H, Li G, Palus B, Seshadri V, Kim S, Gascoyne R, Levy S, Mukhopadhyay M, Dunson D, Dave S. The whole genome landscape of Burkitt lymphoma subtypes. Blood. 2019;
16.
Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 2013;8(12):e83244. PMCID: PMC3862727
17.
Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJM, Mungall AJ, Zhao Y, Schein J, Steidl C, Connors JM, Gascoyne RD, Marra MA. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666–3674. PMCID: PMC3643765
18.
Dreval K, Hilton LK, Cruz M, Shaalan H, Ben-Neriah S, Boyle M, Collinge B, Coyle KM, Duns G, Farinha P, Grande BM, Meissner B, Pararajalingam P, Rushton CK, Slack GW, Wong J, Mungall AJ, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns. Blood. 2023 Aug 10;142(6):561–573. PMCID: PMC10644066
19.
Qiu Z, Khalife J, Ethiraj P, Jaafar C, Lin AP, Holder KN, Ritter JP, Chiou L, Huelgas-Morales G, Aslam S, Zhang Z, Liu Z, Arya S, Gupta YK, Dahia PLM, Aguiar RCT. IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes. Sci Adv. 2024 Jul 12;10(28):eadk2091. PMCID: PMC11244530
20.
Meriranta L, Sorri S, Huse K, Liu X, Spasevska I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandaric L, Karjalainen-Lindsberg ML, Hyytiainen M, Varjosalo M, Myklebust JH, Leppa S. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma. Blood Cancer Discov. 2024 Apr 17;
21.
Ganapathi KA, Jobanputra V, Iwamoto F, Jain P, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, Mansukhani MM, Bhagat G. The genetic landscape of dural marginal zone lymphomas. Oncotarget. Impact Journals; 2016 May 27;7(28):43052–43061.
22.
Li J, Chin CR, Ying HY, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu CS, Jiang Y, Eagles J, Passerini V, Tang Z, Rivas MA, Weigert O, Pugh TJ, Chadburn A, Steidl C, Scott DW, Roeder RG, Mason CE, Zappasodi R, Béguelin W, Melnick AM. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024 Apr 3;15(1):2879. PMCID: PMC10991284
23.
Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM, Cleary KLS, Thomas N, Hilton LK, Michaud N, Daigle S, Davidson J, Bushell K, Yu S, Rys RN, Jain M, Shepherd L, Marra MA, Kuruvilla J, Crump M, Mann K, Assouline S, Connors JM, Steidl C, Cragg MS, Scott DW, Johnson NA, Morin RD. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020 Jul 14;4(13):2886–2898. PMCID: PMC7362366
24.
Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Croce LD, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. PNAS. 2013;110(45):18250–18255.
25.
Shin SY, Lee ST, Kim HJ, Ki CS, Jung CW, Kim JW, Kim SH. BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. Ann Lab Med. 2015 Mar;35(2):257–259. PMCID: PMC4330180
26.
Ying CY, Dominguez-Sola D, Fabi M, Lorenz IC, Bansal M, Califano A, Pasqualucci L, Basso K, Dalla-Favera R. MEF2B Mutations Lead to De-Regulated Expression of the BCL6 Oncogene in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Blood. 120.
27.
Guo B, Huang Y, Duan Y, Liao C, Cen H. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. Cancer Med. 2022 Mar;11(5):1281–1291. PMCID: PMC8894717
28.
Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024 Apr 8;42(4):605–622.e11. PMCID: PMC11003852
29.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017 Oct;171(2):481–494.e15. PMCID: PMC5659841
30.
Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A, Woessmann W. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt’s lymphoma in children. Leukemia. 2004 Mar;18(3):584–588.
31.
Xia M, David L, Teater M, Gutierrez J, Wang X, Meydan C, Lytle A, Slack GW, Scott DW, Morin RD, Onder O, Elenitoba-Johnson KSJ, Zamponi N, Cerchietti L, Lu T, Philippar U, Fontan L, Wu H, Melnick AM. BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. Cancer Discov. 2022 Aug 5;12(8):1922–1941. PMCID: PMC9357155
32.
Guo D, Hong L, Ji H, Jiang Y, Lu L, Wang X, Huang H. The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. J Inflamm Res. 2022;15:1757–1769. PMCID: PMC8923029
33.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan;463(7277):88–92. PMCID: PMC2845535
34.
Khodabakhshi AH, Morin RD, Fejes AP, Mungall AJ, Mungall KL, Bolger-Munro M, Johnson NA, Connors JM, Gascoyne RD, Marra MA, Birol I, Jones SJM. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319. PMCID: PMC3717795
35.
Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P, Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P, Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R, Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Molecular Cell. 2021;
36.
de Miranda NFCC, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, Lisboa S, Enblad G, Teixeira MR, Zeng Y, Peng R, Pan-Hammarström Q. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014 Oct 16;124(16):2544–2553. PMCID: PMC4199956
37.
Gomez F, Fisk B, McMichael JF, Mosior M, Foltz JA, Skidmore ZL, Duncavage EJ, Miller CA, Abel H, Li YS, Russler-Germain DA, Krysiak K, Watkins MP, Ramirez CA, Schmidt A, Martins Rodrigues F, Trani L, Khanna A, Wagner JA, Fulton RS, Fronick CC, O’Laughlin MD, Schappe T, Cashen AF, Mehta-Shah N, Kahl BS, Walker J, Bartlett NL, Griffith M, Fehniger TA, Griffith OL. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma. Cancer Res Commun. 2023 Nov 15;3(11):2312–2330. PMCID: PMC10648575
38.
Bohle V, Döring C, Hansmann M-L, Küppers R. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma. Leukemia. 2013 Mar;27(3):671–679.
39.
Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, Barta S, Bartlett NL, Bethony J, Bhatia K, Bowen J, Bryan AC, Cesarman E, Casper C, Chadburn A, Cruz M, Dittmer DP, Dyer MA, Farinha P, Gastier-Foster JM, Gerrie AS, Grande BM, Greiner T, Griner NB, Gross TG, Harris NL, Irvin JD, Jaffe ES, Henry D, Huppi R, Leal FE, Lee MS, Martin JP, Martin MR, Mbulaiteye SM, Mitsuyasu R, Morris V, Mullighan CG, Mungall AJ, Mungall K, Mutyaba I, Nokta M, Namirembe C, Noy A, Ogwang MD, Omoding A, Orem J, Ott G, Petrello H, Pittaluga S, Phelan JD, Ramos JC, Ratner L, Reynolds SJ, Rubinstein PG, Sissolak G, Slack G, Soudi S, Swerdlow SH, Traverse-Glehen A, Wilson WH, Wong J, Yarchoan R, ZenKlusen JC, Marra MA, Staudt LM, Scott DW, Morin RD. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023 Feb 23;141(8):904–916. PMCID: PMC10023728
40.
Seeberger H, Starostik P, Schwarz S, Knörr C, Kalla J, Ott G, Müller-Hermelink HK, Greiner A. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab Invest. 2001 Jul;81(7):977–986.
41.
Scholl V, Stefanoff CG, Hassan R, Spector N, Renault IZ. Mutations within the 5’ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2007 May;48(5):957–963.
42.
Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011 Jul 31;43(9):830–837. PMCID: PMC3297422
43.
Jingjing Z, Lei M, Jie Z, Sha C, Yapeng H, Weimin Z, Chunluan Y. A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression. Naunyn Schmiedebergs Arch Pharmacol. 2020 Aug;393(8):1549–1558.
44.
Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018 Oct 1;9(1):4001. PMCID: PMC6167379
45.
Giallongo A, Appella E, Ricciardi R, Rovera G, Croce CM. Identification of the c-myc oncogene product in normal and malignant B cells. Science. 1983 Oct 28;222(4622):430–432.
46.
Christie L, Kernohan N, Levison D, Sales M, Cunningham J, Gillespie K, Batstone P, Meiklejohn D, Goodlad J. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? Leuk Lymphoma. 2008 Mar;49(3):470–476.
47.
Johnston JM, Carroll WL. C-myc hypermutation in Burkitt’s lymphoma. Leuk Lymphoma. 1992 Dec;8(6):431–439.
48.
Thomas RK, Wickenhauser C, Tawadros S, Diehl V, Küppers R, Wolf J, Schmitz R. Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma. Br J Haematol. 2004 Jul;126(1):50–54.
49.
Flori M, Schmid CA, Sumrall ET, Tzankov A, Law CW, Robinson MD, Müller A. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood. 2016 Mar 17;127(11):1438–1448.